With over $1B of capital, Prospect Venture Partners focuses on investing in biotech and healthcare startups, particularly those in the United States. They typically invest in rounds with 4-5 participants and have funded companies like Kythera Biopharmaceuticals and NGM Biopharmaceuticals. The firm prefers startups that are 4-5 years old and have a smaller number of founders. They have a track record of successful exits and have been active in the industry since 2004, with deals ranging from $10-50 million. The firm was founded by Alex Barkas and has a team of experienced managing directors and a CFO.